UK-based Verdiva Bio Limited has announced its launch as a clinical-stage biopharma company, backed by an oversubscribed Series A financing of USD 411 million. The round was co-led by Forbion and General Atlantic, with additional investments from RA Capital Management, OrbiMed, Logos Capital, Lilly Asia Ventures, and LYFE Capital.
Product Pipeline
Verdiva boasts a robust pipeline of three candidate products, whose global development and commercialization rights outside of greater China and South Korea were acquired from China-based Sciwind Biosciences in 2024. The products include:
- A Phase II-ready, potential first-in-class, once-weekly oral GLP-1 receptor agonist.
- A potential first-in-class, once-weekly oral amylin agonist.
- A long-acting, subcutaneous amylin agonist.
Significance of the Financing
The USD 411 million Series A financing round underscores Verdiva Bio’s commitment to advancing its clinical-stage biopharma pipeline. This significant funding will support the development and commercialization of its innovative products, potentially offering new treatment options for patients in need.-Fineline Info & Tech
